Online ISSN: 2515-8260

Keywords : Insulin Resistance Syndrome


A. Praveen Naik, Md. Masood Ahmed Shareef

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 1640-1648

Background: Non-alcoholic steatohepatitis is a clinicopathological syndrome, characterized by the development of histological features comparable to those induced by excessive alcohol intake without alcohol abuse. This study is an attempt to evaluate the clinical, biochemical and histological profile of non-alcoholic steatohepatitis in this tertiary hospital in Rayalasema.
Material and Methods: Present study was single-center, prospective, observational study, conducted in patients of all ages, either gender, who are found to have increased echo texture of liver on routine ultra-sound scan.
Results: The present study was conducted on 60 patients, comprised of 36(60%) males and 24(40%) females. Majority were from the age group of 41 to 50 years there were 22 (36.66%) cases of which 12 (54.54%) were males and 10 (45.46%) were females.  The commonest symptom was fatigability and malaise (66.66%), followed by right upper abdominal discomfort (46.66%), Jaundice (10%), ascites (10%), UGI Bleed (8.3%) patients and 20 (33.33%) patients were asymptomatic at the time of diagnosis and diagnosis was established due to abnormal sonographic finding and abnormal liver function tests during investigations for other causes. Hyperlipidemia (61.67%), diabetes mellitus (58.33%), obesity (46.67%) & overweight (50%) were the most commonly associated risk factors noted. 7 patients underwent biopsy. Of these 4.28% patient showed steatohepatitis, 42.86% patients showed simple fatty change and 14.28% patient had cirrhosis. Other 28.57% had no specific changes.
Conclusion: This study demonstrates that features suggestive of the metabolic syndrome are observed more frequently in patients with non-alcoholic steatohepatitis, share many of the systemic disorders that constitute insulin resistance syndrome, hyperlipidemia, hypertension, obesity, type 2 diabetes and hepatic steatosis.